The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder
Open accessAbstract
OBJECTIVE: Hyperactivity, impulsiveness, and distractibility are common problems in children with autism spectrum disorder (ASD). Extended-release guanfacine is approved for children with attention deficit hyperactivity disorder but not well studied in ASD. METHOD: In a multisite, randomized clinical trial, extended-release guanfacine was compared with placebo in children with ASD accompanied by hyperactivity, impulsiveness, and distractibility. RESULTS: Sixty-two subjects (boys, N=53; girls, N=9; mean age=8.5 years [SD=2.25]) were randomly assigned to guanfacine (N=30) or placebo (N=32) for 8 weeks. The guanfacine group showed a 43.6% decline in scores on the Aberrant Behavior Checklist-hyperactivity subscale (least squares mean from 34.2 to 19.3) compared with a 13.2% decrease in the placebo group (least squares mean from 34.2 to 29.7; effect size=1.67). The rate of positive response (much improved or very much improved on the Clinical Global Impression-Improvement scale) was 50% (15 of 30) for guanfacine compared with 9.4% (3 of 32) for placebo. A brief cognitive battery tapping working memory and motor planning showed no group differences before or after 8 weeks of treatment. The modal dose of guanfacine at week 8 was 3 mg/day (range: 1-4 mg/day), and the modal dose was 3 mg/day (range: 2-4 mg/day) for placebo. Four guanfacine-treated subjects (13.3%) and four placebo subjects (12.5%) exited the study before week 8. The most common adverse events included drowsiness, fatigue, and decreased appetite. There were no significant changes on ECG in either group. For subjects in the guanfacine group, blood pressure declined in the first 4 weeks, with return nearly to baseline by endpoint (week 8). Pulse rate showed a similar pattern but remained lower than baseline at endpoint. CONCLUSIONS: Extended-release guanfacine appears to be safe and effective for reducing hyperactivity, impulsiveness, and distractibility in children with ASD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A large trial of balovaptan, a vasopressin AVPR1A antagonist in adults with ASD showed negative results on its primary outcome ( a general rating of ASD symptoms), with suggestive results on a key secondary parent report measure of adaptive behaviour, including social and communication behaviour 212 .”
From Autism spectrum disorder (2020) · cites this paper as [212]
In the citing paper
“The results of this trial indicated that guanfacine ER is safe and efficacious for the short-term treatment of ADHD symptoms in children and adolescents with ASD [83].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [83]
In the citing paper
“The guanfacine group had a 50% positive response rate on the Clinical Global Impressions-Improvement (CGI-I) scale compared to 9.4% for placebo.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [83]
In the citing paper
“ABC-Hyperactivity subscale scores fell by 43.6% in the active treatment group and 13.2% in the placebo group.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [83]
In the citing paper
“Drowsiness, fatigue, emotional/tearful presentation, dry mouth, and irritability were the most common side effects in the active treatment arm.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [83]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Leventhal, B. L., DiLavore, P. C., Pickles, A., & Rutter, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005592401947 · Cited by 7,520
Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318179964f · Cited by 3,399
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Global Prevalence of Autism and Other Pervasive Developmental Disorders
Elsabbagh, M., Divan, G., Koh, Y., Kim, Y. S., Kauchali, S., Marcín, C., Montiel‐Nava, C., Patel, V., Paula, C. S., Wang, C., et al. (2012) · Autism Research · doi:10.1002/aur.239 · Cited by 2,636
Mullen Scales of Early Learning
Bradley-Johnson, S. (1997) · Psychology in the Schools · doi:10.1002/(sici)1520-6807(199710)34:4<379::aid-pits14>3.0.co;2-e · Cited by 2,325
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Thompson Coon, J. (2002) · Focus on Alternative and Complementary Therapies · doi:10.1111/j.2042-7166.2002.tb05480.x · Cited by 1,744
Stanford-Binet Intelligence Scale
(2012) · SpringerReference · doi:10.1007/springerreference_70151 · Cited by 1,664
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Self-citation
Research works printed but not linked: 7
- American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders-Text Revised
- Sparrow SS, 2005, Vineland-II Adaptive Behavior Scales
- Aman MG, 1985, Am J Ment Defic, 89, 485
- Elliott C, 2007, Differential Ability Scales-II (DAS-II)
- Korkman M, 2007, NEPSYII: Administration Manual
- Board AW, 1988, Clin Ther, 10, 761
- 10.1093/biostatistics/kxh001 · DOI · Paper page
Cited by
Lord, C., Elsabbagh, M., Baird, G., & Veenstra-Vanderweele, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31129-2 · Cited by 2,819
Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
Autism Spectrum Disorder: A Review
Hirota, T., & King, B. H. (2023) · JAMA · doi:10.1001/jama.2022.23661 · Cited by 957
Self-citationThe Lancet Commission on the future of care and clinical research in autism
Lord, C., Charman, T., Havdahl, A., Carbone, P., Anagnostou, E., Boyd, B., Carr, T., de Vries, P. J., Dissanayake, C., Divan, G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01541-5 · Cited by 924
Self-citation
Metadata
- Authors
- Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., Sanders, R., Minjarez, M., Cowen, J., Mullett, J., Page, C., Ward, D., Deng, Y., Loo, S., Dziura, J., McDougle, C. J., & Research Units on Pediatric Psychopharmacology Autism Network
- Affiliations
- Seattle Children's Hospital (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2015-12-01
- Volume
- 172
- Issue
- 12
- Pages
- 1197-1206
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1933613998
- Cited by
- 201
- References
- 38
- Citations by year
- 2026: 12 · 2025: 21 · 2024: 24 · 2023: 18 · 2022: 21 · 2021: 22 · 2020: 25 · 2019: 15 · 2018: 14 · 2017: 11 · 2016: 16 · 2015: 2
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Yale University
- National Institutes of Health (UL1TR000454)
- National Institute of Mental Health (R01MH86927, R01MH086927, R01MH83739, R01MH083707, R01MH083739, R01MH083747)
- National Center for Research Resources (UL1RR024139)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
- Keywords
- guanfacine, autism spectrum disorder, hyperactivity, impulsivity, distractibility, ADHD medication, Aberrant Behavior Checklist, working memory, motor planning, blood pressure, adverse events, children
- MeSH terms
- Autism Spectrum Disorder, Adolescent, Child, Child, Preschool, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Hyperkinesis, Male, Memory, Short-Term, Neuropsychological Tests, Psychomotor Performance, Guanfacine, Treatment Outcome, Adrenergic alpha-2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. https://app.cochat.ai/papers/10.1176/appi.ajp.2015.15010055
- The paper
- Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., Sanders, R., Minjarez, M., Cowen, J., Mullett, J., Page, C., Ward, D., Deng, Y., Loo, S., Dziura, J., McDougle, C. J., & Research Units on Pediatric Psychopharmacology Autism Network. (2015). Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2015.15010055
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.